Evidence map›Paper›PMID 31919565›Full record

SynthesisJournal of neurology2020

Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.

Lili Kokoti, Konstantina Drellia, Dimitrios Papadopoulos, Dimos D Mitsikostas

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. The Nocebo Effect.Annual review of pharmacology and toxicology · 2024
    Review
  7. Article
  8. The sense of stopping migraine prophylaxis.The journal of headache and pain · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lili Kokoti1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 V. Sofia's Avenue, 11528, Athens, Greece.ORCID http://orcid.org/0000-0002-9136-1367
Konstantina Drellia1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 V. Sofia's Avenue, 11528, Athens, Greece.ORCID http://orcid.org/0000-0002-3922-5552
Dimitrios PapadopoulosNeurology Clinic, Athens Medical Center-Paleo Phaliro Clinic, Athens, Greece.ORCID http://orcid.org/0000-0003-1806-7740
Dimos D Mitsikostas1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 V. Sofia's Avenue, 11528, Athens, Greece. dmitsikostas@med.uoa.gr.ORCID http://orcid.org/0000-0002-4691-3388
National and Kapodistrian University of Athens · GRAthens Medical Center · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High placebo and low nocebo phenomena mirror high positive expectations for a novel treatment, among other reasons. In a meta-analysis aimed to identify placebo and nocebo phenomena in the placebo-controlled randomized trials (RCTs) with the monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) all the placebo-treated patients were pooled and compared with the placebo-treated patients in RCTs with topiramate and onabotulinum toxin A (OBTA). In episodic migraine (EM), the proportion of placebo-treated patients who achieved the 50% responder rate (placebo) was 32.7% (95% CI 28.6%-37.0%) in anti-CGRP mAbs vs. 24.4% (95% CI 20.5%-28.5%) in topiramate trials. The proportion of dropouts due to adverse events in placebo-treated patients (nocebo) was 1.9% (95% CI 1.4%-2.6%) in anti-CGRP mAbs vs. 9.9% (95% CI 7.7%-12.3%) in topiramate RCTs. In chronic migraine (CM), the placebo 50% responder rate was 23.6% (95% CI 11.2%-38.8%) in anti-CGRP mAbs RCTs vs. 36.4% (95% CI 32.6%-39.3%) in RCTs with OBTA. The nocebo dropout in anti-CGRP mAbs and OBTA RCTs was 1.4% (95% CI 0.8%-2.1%) and 0.9 (95% CI 0.3%-1.7%), respectively. The stronger placebo and weaker nocebo phenomena in RCTs with anti-CGRP mAbs vs. those with topiramate in the prophylaxis of EM, may decisively determine anti-CGRP mAbs treatment success. No differences were detected between the anti-CGRP mAbs and OBTA in the treatment of CM.

Indexed as

Placebo EffectRandomized Controlled Trials as TopicAnalgesics, Non-NarcoticAntibodies, MonoclonalAnticonvulsantsCalcitonin Gene-Related PeptideHumansMigraine DisordersNeuromuscular AgentsNocebo EffectOutcome Assessment, Health CareAnalgesics, Non-NarcoticAntibodies, MonoclonalAnticonvulsantsCalcitonin Gene-Related PeptideNeuromuscular AgentsAnti-calcitonin gene-related peptide (CGRP) monoclonal antibodiesChronic migraineEpisodic migraineOnabotulinum toxin ATopiramateTreatment

Identifiers

PMID31919565
OpenAlexW2999319162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.